7272 Yamaha Motor Co. Ltd.

Yamaha Motor Establishes New Company in the Medical and Healthcare Field Specializing in Antibodies

Yamaha Motor Co., Ltd. (Tokyo: 7272) announced today that the Company has established Tuning Fork Bio Inc. in Delaware, USA (CEO: Yuichi HIKICHI), which will analyze the antibodies in blood to better visualize people’s health conditions through its antibody profiling business. The main target markets for this new company are the U.S. and Japan. Using Tuning Fork Bio’s antibody analysis technology and expertise, antibodies--a type of protein--that manifest for specific diseases are selected and compared with a patient’s own antibodies in order to analyze their current health condition, i.e., antibody profiling. This information will bring benefits to health checkups conducted by medical institutions, help in selecting the best drugs for patients, and aid in new drug research by pharmaceutical companies.

This press release features multimedia. View the full release here:

Tuning Fork Bio, a new medical and healthcare company from Yamaha Motor (Graphic: Business Wire)

Tuning Fork Bio, a new medical and healthcare company from Yamaha Motor (Graphic: Business Wire)

Tuning Fork Bio will launch its business in collaboration with the Translational Research Center (hereinafter, “TR Center”) at Fukushima Medical University. The TR Center has developed protein microarrays utilizing technology that transfers proteins onto glass slides at high densities (more than 10,000 types). By measuring the binding state of proteins (antigens) on the microarray with the antibodies in the blood, it is possible to comprehensively search for the antibodies an individual has in their body. Exceeding 20,000 types in total, the number of protein samples the TR Center has prepared is among the highest in the world (according to Yamaha Motor research), and includes not only human proteins but also proteins from viruses and bacteria.

Tuning Fork Bio analyzes protein microarray data using proprietary bioinformatics technology to select antibodies suitable for use as indicators, i.e., biomarkers, for assessing health conditions, diagnoses, etc., and constructs systems applicable for performing diagnoses.

By comparing an individual’s antibodies with data when sick and data when healthy, we can make health risks easier to perceive. Tuning Fork Bio aims to offer diagnostic services aiding more positive life planning for people by helping prevent the onset of sickness and facilitating the selection of medications that best fit each individual’s conditions.

EN
27/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Yamaha Motor Co. Ltd.

 PRESS RELEASE

Yamaha Motor Launches New Five-seater Electric Golf Cars with New In-h...

IWATA, Japan--(BUSINESS WIRE)-- Yamaha Motor Co., Ltd. (Tokyo: 7272) announced today that it will launch the new five-seater electric golf carts, G30Es and G31EPs, in Japan in June 2025. The company is also planning to introduce both models to the Taiwanese market at a later date. The new lineup consists of the electromagnetically*¹ guided G30Es and the manually operated G31EPs, both equipped with a newly developed lithium-ion battery and a vehicle control unit. In addition to the inherent quietness of an electric vehicle, the adoption of a high-performance AC motor with superior speed and tor...

 PRESS RELEASE

Yamaha Motor Launches Motorcycle Industry's First Carbon-Neutral Paint...

IWATA, Japan--(BUSINESS WIRE)-- Yamaha Motor Co., Ltd. (Tokyo:7272) has newly established the CN1 carbon-neutral mass-production painting line at its Iwata Main Factory, and began painting motorcycle fuel tanks on February 20. The new painting line uses electricity for all processes that previously used fossil fuels, including pre-treatment, painting, baking, and drying. CN1 is also the motorcycle industry's first all-electric product painting line in operation (according to Yamaha Motor research). This press release features multimedia. View the full release here: CN1, the motorcycle industr...

 PRESS RELEASE

Yamaha Motor : résumé des résultats consolidés pour l’exercice fiscal ...

IWATA, Japon--(BUSINESS WIRE)-- Yamaha Motor Co., Ltd. (Tokyo : 7272) annonce ses résultats commerciaux consolidés pour l’ensemble de l’exercice 2024. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : Yamaha Motor Headquarters, Iwata, Shizuoka, Japan (Photo: Business Wire) Le chiffre d’affaires s’est élevé à 2 576,2 milliards de yens (soit une augmentation de 161,4 milliards de yens ou 6,7 % par rapport à l’exercice précédent) en raison de l’augmentation des ventes unitaires et des prix unitaires plus élevés pour les modèles vendus au Brésil et en Ind...

 PRESS RELEASE

Yamaha Motor: Consolidated Business Results Summary ‐ Full Fiscal Year...

IWATA, Japan--(BUSINESS WIRE)-- Yamaha Motor Co., Ltd. (Tokyo: 7272) announces its consolidated business results for the full 2024 fiscal year. This press release features multimedia. View the full release here: Yamaha Motor Headquarters, Iwata, Shizuoka, Japan (Photo: Business Wire) Revenues were 2,576.2 billion yen (an increase of 161.4 billion yen or 6.7% compared with the previous fiscal year) due to more unit sales and higher prices per unit for models sold in Brazil and India in our core business of motorcycles. As for operating income, after recording the effects soaring prices had o...

 PRESS RELEASE

Yamaha Motor to Debut CELL HANDLER™ 2 at SLAS2025 in USA

IWATA, Japan--(BUSINESS WIRE)-- Yamaha Motor Co., Ltd. (Tokyo: 7272) announced today that it will exhibit the CELL HANDLER™ 2, a cell picking and imaging system, at SLAS2025, marking the product's first overseas exhibition. SLAS2025, one of the world’s largest conferences and exhibitions on automation technologies in life sciences and drug discovery research, will be held in San Diego, USA, from Monday, January 27, to Wednesday, January 29. This press release features multimedia. View the full release here: CELL HANDLER (TM) 2 *For research use only. Not for use in diagnostic or therapeutic p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch